logo
Takeda’sZasocitinibSignificantlyOutperformsDeucravacitinibinHead-to-HeadPhase3PsoriasisStudy,PromisingtoRedefineOralTreatmentExpectations
===2026/6/12 9:58:16===
Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have or Have Not Been Treated With Biologic Medicines. ClinicalTrials.gov Identifier: NCT06671496. Updated April 6, 2026. Accessed June 2026. https://clinicaltrials.gov/study/NCT06671496.

A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Crohn's Disease. ClinicalTrials.gov Identifier: NCT06233461. Updated May 8, 2026. Accessed June 2026. https://clinicaltrials.gov/study/NCT06233461.

A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Ulcerative Colitis. ClinicalTrials.gov Identifier: NCT06254950. Updated May 6, 2026. Accessed June 2026. https://www.clinicaltrials.gov/study/NCT06254950.

A Study of Zasocitinib in Adults With Nnsegmental Vitiligo. ClinicalTrials.gov Identifier: NCT07108283. Updated May 13, 2026. Accessed J
=*=*=*=*=*=
当前为第19/21页
下一页-上一页-
=*=*=*=*=*=
返回新闻列表
返回网站首页